LLY | tickerfilter.com

Fundamental analysis

69%

Profitability 75%

Dept financing 25%

Liquidity 54%

Performance 77%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.37%

1 Month

6.49%

3 Months

-4.82%

6 Months

-3.23%

1 Year

32.68%

2 Year

30.64%

Key data

Stock price

$989.87

P/E Ratio

32.60

DAY RANGE

$971.18 - $997.52

EPS

$28.20

52 WEEK RANGE

$623.78 - $1,133.95

52 WEEK CHANGE

$38.34

MARKET CAP

824.022 B

YIELD

0.68%

SHARES OUTSTANDING

941.741 M

DIVIDEND

$1.73

EX-DIVIDEND DATE

05-15-2026

NEXT EARNINGS DATE

08-07-2025

BETA

0.81

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,444,574

AVERAGE 30 VOLUME

$3,449,043

Company detail

CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

LLY - ELI LILLY & Co